Sorafenib - induced thyroiditis in patient with a relapse of acute myelomonocytic leukemia with FLT3-ITD mutation


如何引用文章

全文:

详细

Sorafenib has been used in acute myeloid leukemias with FLT3-ITD mutation improving the outcomes. However the high incidence of treatment - emergent adverse event may be associated with treatment using sorafenib with cytotoxic chemotherapy. We have reported a case of severe thyroiditis in patient with a relapse of acute myelomonocytic leukemia.

作者简介

Ya Balzhanova

National Research Center for Hematology

врач-гематолог отд-ния интенсивной высокодозной химиотерапии гематологических заболеваний с круглосуточным и дневным стационарами ФГБУ «НМИЦ гематологии»; ORCID: 0000-0001-8973-9407 Moscow, Russia

E Parovichnikova

National Research Center for Hematology

д.м.н., врач-гематолог, зав. отд. химиотерапии гемобластозов, депрессий кроветворения и трансплантации костного мозга ФГБУ «НМИЦ гематологии»; ORCID: 0000-0001-6177-3566 Moscow, Russia

A Sokolov

National Research Center for Hematology

к.м.н., врач-гематолог, с.н.с. отд-ния интенсивной высокодозной химиотерапии гемобластозов и депрессий кроветворения с круглосуточным и дневным стационарами ФГБУ «НМИЦ гематологии»; ORCID: 0000-0003-1494-7978 Moscow, Russia

V Ryzhko

National Research Center for Hematology

к.м.н., врач-гематолог отд-ния интенсивной высокодозной химиотерапии гематологических заболеваний с круглосуточным и дневным стационарами ФГБУ «НМИЦ гематологии»; ORCID: 0000-0003-1221-3495 Moscow, Russia

M Samtsova

National Research Center for Hematology

врач-гематолог отд-ния интенсивной высокодозной химиотерапии гематологических заболеваний с круглосуточным и дневным стационарами ФГБУ «НМИЦ гематологии»; ORCID: 0000-0001-9984-389X Moscow, Russia

E Gribanova

National Research Center for Hematology

к.м.н., врач-гематолог, зав. отд-нием интенсивной высокодозной химиотерапии гематологических заболеваний с круглосуточным и дневным стационарами ФГБУ «НМИЦ»; ORCID: 0000-0002-4155-7820 Moscow, Russia

参考

  1. O’Donnell M.R, Tallman M.S, Abboud C.N, Altman J.K, Appelbaum F.R, Arber D.A, Bhatt V, Bixby D, Blum W, Coutre S.E, de Lima M, Fathi A.T, Fiorella M, Foran J.M, Gore S.D, Hall A.C, Kropf P, Lancet J, Maness L.J, Marcucci G. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. J Nat Comprehens Cancer Network. 2017;15(7):926-57. doi: 10.6004/jnccn.2017.0116
  2. Gu T, Nardone J, Wang Y, Loriaux M, Villén J, Beausoleil S, Tucker M, Kornhauser J, Ren J, Mac Neill J, Gygi S, Druker B, Heinrich M, Rush J, Polakiewicz R. Survey of activated FLT3 signaling in leukemia. PLoS One. 2011;6(4):e19169. doi: 10.1371/journal.pone.0019169
  3. Shih L.Y, Huang C.F, Wu J.H, Lin T.L, Dunn P, Wang P.N, Kuo M.C, Lai C.L, Hsu H.C. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood. 2002;100(7):2387-92. doi: 10.1182/blood-2002-01-0195
  4. Nazha A, Cortes J, Faderl S, Pierce S, Daver N, Kadia T, Borthakur G, Luthra R, Kantarjian H, Ravandi F. Activating internal tandem duplication mutations of the fms - like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica. 2012;97(8):1242-5. doi: 10.3324/haematol.2012.062638
  5. Stone R.M, Mandrekar S.J, Sanford B.L, Laumann K, Geyer S, Bloomfield C.D, Thiede C, Prior T.W, Döhner K, Marcucci G, Lo-Coco F, Klisovic R.B, Wei A, Sierra J, Sanz M.A, Brandwein J.M, de Witte T, Niederwieser D, Appelbaum F.R, Medeiros B.C, Tallman M.S, Krauter J, Schlenk R.F, Ganser A, Serve H, Ehninger G, Amadori S, Larson R.A, Döhner H. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017;377(5):454-64. doi: 10.1056/NEJMoa1614359
  6. Altman J.K, Foran J.M, Pratz K.W, Trone D, Cortes J.E, Tallman M.S. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2018;93(2):213-21. doi: 10.1002/ajh.24974
  7. Румянцев П.О. Роль таргетной терапии мультикиназными ингибиторами в лечении резистентного к радиойодтерапии дифференцированного рака щитовидной железы. Клиническая и экспериментальная тиреоидология. 2015;11(2):25-32. doi: 10.14341/ket2015225-32
  8. Al-Kali A, Cortes J, Faderl S, Jones D, Abril C, Pierce S, Brandt M, Kantarjian H, Ravandi F. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. Clin Lymph Myel Leuk. 2011;11(4):361-6. doi: 10.1016/j.clml.2011.06.007
  9. Uy G.L, Mandrekar S.J, Laumann K, Marcucci G, Zhao W, Levis M.J, Klepin H.D, Baer M.R, Powell B.L, Westervelt P, de Angelo D.J, Stock W, Sanford B, Blum W.G, Bloomfield C.D, Stone R.M, Larson R.A. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Advanc. 2017;1(5):331-40. doi: 10.1182/bloodadvances.2016003053
  10. Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus C.D, Brandts C.H, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause S.W, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghan C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel W.E, Ehninger G. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9
  11. Randrup Hansen C, Grimm D, Bauer J, Wehland M, Magnusson N.E. Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma. Int J Mol Sci. 2017;18(2):461. doi: 10.3390/ijms18020461
  12. Юсупова Р.А., Подольская Т.Б. Ультразвуковое исследование аутоиммунного тиреоидита в амбулаторных условиях. Практическая медицина. 2017;(2):130-3.
  13. Fallahi P, Ferrari S.M, Vita R, Di Domenicantonio A, Corrado A, Benvenga S, Antonelli A. Thyroid dysfunctions induced by tyrosine kinase inhibitors. Exp Opin Drug Saf. 2014;13(6):723-33. doi: 10.1517/14740338.2014.913021
  14. Van Doorn L, Eskens F.A, Visser T.J, van der Lugt A, Mathijssen R.H, Peeters R.P. Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid. 2011;21(2):197-202. doi: 10.1089/thy.2010.0234
  15. Takahashi H, Nasu K, Minami M, Kojima T, Nishiyama H, Ishiguro T, Konishi T. Organ atrophy Induced by sorafenib and sunitinib - quantitative computed tomography (CT) evaluation of the pancreas, thyroid gland and spleen. Pol J Radiol. 2016;81:557. doi: 10.12659/PJR.898936
  16. Iavarone M, Perrino M, Viganò M, Beck-Peccoz P, Fugazzola L. Sorafenib - induced destructive thyroiditis. Thyroid. 2010;20(9):1043-4. doi: 10.1089/thy.2010.0070 PMID: 20825302
  17. Sun J, Hu J, Huang Y, Ying S.W, Han X.Y, Zheng Y.L, Huang H. Sorafenib - induced thyroiditis in FMS-like tyrosine kinase 3-internal tandem duplication - mutated acute myeloid leukemia. Chin Med J. 2016;129(20):2512. doi: 10.4103/0366-6999.191831
  18. Mooij C.F, Netea-Maier R.T, ten Broek R, Gotthardt M, Hagleitner M.M. Pancytopenia and hypothyroidism in a patient with leukemic infiltration of the thyroid as the first presentation of acute lymphoblastic leukemia. J Ped Hematol Oncol. 2018;40(2):145-7. doi: 10.1097/MPH.0000000000000869
  19. Sen R, Gupta S, Batra A, Gill M, Gupta V, Marwah N. Acute lymphoblastic leukaemia (ALL) with infiltration of the thyroid: a cytological diagnosis. Endocr Pathol. 2012;23(4):268-9. doi: 10.1007/s12022-012-9206-y

版权所有 © Consilium Medicum, 2019

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 
 


##common.cookie##